The FDA approved the CD19-directed chimeric antigen receptor (CAR) T-cell immunotherapy lisocabtagene maraleucel (Breyanzi, Bristol Myers Squibb [BMS]) for the treatment of adults with relapsed or refractory (R/R) large B-cell lymphoma after two or more lines of systemic therapy.
“Lisocabtagene maraleucel produced sustained responses in a significant proportion of patients with relapsed or refractory large B-cell lymphoma” in the TRANSCEND NHL 001 trial, said Jeremy Abramson, MD,